A new trading day began on Monday, with Allogene Therapeutics Inc (NASDAQ: ALLO) stock price up 1.29% from the previous day of trading, before settling in for the closing price of $1.55. ALLO’s price has ranged from $1.23 to $3.78 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -43.16% over the last five years. Meanwhile, its annual earnings per share averaged 8.21%. With a float of $142.26 million, this company’s outstanding shares have now reached $212.21 million.
The firm has a total of 229 workers. Let’s measure their productivity. In terms of profitability, gross margin is -32622.73%, operating margin of -1219136.36%, and the pretax margin is -1168850.0%.
Allogene Therapeutics Inc (ALLO) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Allogene Therapeutics Inc is 34.52%, while institutional ownership is 63.36%. The most recent insider transaction that took place on Apr 21 ’25, was worth 13,537. In this transaction SVP, Finance of this company sold 9,601 shares at a rate of $1.41, taking the stock ownership to the 130,663 shares. Before that another transaction happened on Apr 21 ’25, when Company’s Officer proposed sale 9,601 for $1.41, making the entire transaction worth $13,537.
Allogene Therapeutics Inc (ALLO) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.69% during the next five years compared to 6.26% growth over the previous five years of trading.
Allogene Therapeutics Inc (NASDAQ: ALLO) Trading Performance Indicators
Here are Allogene Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17055.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.27 in one year’s time.
Technical Analysis of Allogene Therapeutics Inc (ALLO)
Analysing the last 5-days average volume posted by the [Allogene Therapeutics Inc, ALLO], we can find that recorded value of 1.76 million was lower than the volume posted last year of 4.8 million. As of the previous 9 days, the stock’s Stochastic %D was 51.94%. Additionally, its Average True Range was 0.14.
During the past 100 days, Allogene Therapeutics Inc’s (ALLO) raw stochastic average was set at 13.33%, which indicates a significant decrease from 65.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.57% in the past 14 days, which was lower than the 109.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7476, while its 200-day Moving Average is $2.2681. Now, the first resistance to watch is $1.6217. This is followed by the second major resistance level at $1.6733. The third major resistance level sits at $1.7067. If the price goes on to break the first support level at $1.5367, it is likely to go to the next support level at $1.5033. Now, if the price goes above the second support level, the third support stands at $1.4517.
Allogene Therapeutics Inc (NASDAQ: ALLO) Key Stats
With a market capitalization of 341.11 million, the company has a total of 217,265K Shares Outstanding. Currently, annual sales are 20 K while annual income is -257,590 K. The company’s previous quarter sales were 0 K while its latest quarter income was -59,940 K.
